Economic Burden of Chronic Obstructive Pulmonary Disease
- 1 January 2001
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 19 (3) , 245-254
- https://doi.org/10.2165/00019053-200119030-00003
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Type 1 Cytokines and the Pathogenesis of TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Inhaled Corticosteroids Are Beneficial in Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Quality of life changes in COPD patients treated with salmeterol.American Journal of Respiratory and Critical Care Medicine, 1997
- Definitions, Epidemiology, Pathophysiology, Diagnosis, and StagingAmerican Journal of Respiratory and Critical Care Medicine, 1995
- Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task ForceEuropean Respiratory Journal, 1995
- Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1JAMA, 1994
- In Chronic Obstructive Pulmonary Disease, a Combination of Ipratropium and Albuterol Is More Effective Than Either Agent AloneChest, 1994
- Assessment of reversibility of airway obstruction in patients with chronic obstructive airways disease.Thorax, 1990
- Dose Response to Ipratropium as a Nebulized Solution in Patients with Chronic Obstructive Pulmonary Disease: A Three-Center StudyAmerican Review of Respiratory Disease, 1989
- Antibiotic Therapy in Exacerbations of Chronic Obstructive Pulmonary DiseaseAnnals of Internal Medicine, 1987